SEARCH:   Advanced

Blood, 15 October 2008, Vol. 112, No. 8, pp. 3362-3372. Prepublished online as a Blood First Edition Paper on July 24, 2008; DOI 10.1182/blood-2008-04-149393. This Article Full Text Full Text (PDF) Supplemental Table and Figure All Versions of this Article: blood-2008-04-149393v1 112/8/3362    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Goodyear, O. C. Articles by Moss, P. Search for Related Content PubMed PubMed Citation Articles by Goodyear, O. C. Articles by Moss, P. Related Collections Immunobiology Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma Oliver C. Goodyear1, Guy Pratt1, Andrew McLarnon1, Mark Cook2, Karen Piper1, and Paul Moss1 1 Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham; and 2 Department of Haematology, University Hospital Birmingham National Health Service (NHS) Trust, Birmingham, United Kingdom The factors that determine progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma are unclear but may include the breakdown of immune surveillance. Cancer testis antigens (CTAgs) are expressed by the majority of myelomas and MGUS tumors and are a potential immune target. We have characterized CD4+ and CD8+ T-cell immune responses to MAGE-A1/A2/A3 in these patients. CD4+ T-cell immunity to MAGE proteins is stronger and more frequent in MGUS compared with myeloma with a predominantly CD45RA–CCR7– effector memory profile and cytotoxicity against MAGE-positive cell lines. In contrast CD8+ T-cell immune responses were present almost exclusively in patients with multiple myeloma, correlating with disease, with a CD45RA+CCR7– memory phenotype, localizing poorly to the bone marrow but were able to lyse myeloma cell lines in vitro. This suggests that the CD4+ CTAg-specific immune response may play a role in controlling tumor growth, whereas the efficacy of the CD8+ T-cell response appears to be limited in vivo. Despite this, patients with evidence of a CTAg-specific immune response had a 53% reduction in mortality over a median follow-up of 4 years. These findings have important implications for clinical approaches to CTAg-specific immunotherapy in patients with cancer. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Rezvani, A. S. M. Yong, A. Tawab, B. Jafarpour, R. Eniafe, S. Mielke, B. N. Savani, K. Keyvanfar, Y. Li, R. Kurlander, et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia Blood, March 5, 2009; 113(10): 2245 - 2255. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020